FDA Issues Updated Guidance on Hemodialysis Blood Tubing Sets Premarket Notification [510(k)] Submissions

Date of Publication: 23-Jul-2026 INTELLIGENT OVERVIEWThe U.S. Food and Drug Administration (FDA) has issued an updated guidance document titled "Hemodialysis Blood Tubing Sets – Premarket Notification (510(k)) Submissions: Guidance for…

Continue ReadingFDA Issues Updated Guidance on Hemodialysis Blood Tubing Sets Premarket Notification [510(k)] Submissions

Bhutan BFDA Draft Guideline 2026: Strengthening Medical Product Import Controls

Date of Publication: 22-May-2026 INTELLIGENCE OVERVIEWAgency: Bhutan FDAThe Bhutan Food and Drug Authority (BFDA) has released a draft guideline on the Importation, Consignment Verification, and Lot Release of Medical Products…

Continue ReadingBhutan BFDA Draft Guideline 2026: Strengthening Medical Product Import Controls

FDA Adopts ICH M11 Guidance for Clinical Electronic Structured Harmonized Protocol (CeSHarP)

Date of Publication: 20-May-2026 INTELLIGENCE OVERVIEWAgency: USFDAThe FDA has released the ICH M11 Clinical Electronic Structured Harmonized Protocol (CeSHarP) Guidance for Industry, introducing a standardized approach for structuring and electronically…

Continue ReadingFDA Adopts ICH M11 Guidance for Clinical Electronic Structured Harmonized Protocol (CeSHarP)

India Updates Schedule H1: Pregabalin Added Under Drugs Rules, 1945

Date of Publication: 13-May-2026 INTELLIGENCE OVERVIEW:Agency: CDSCO (India)The Government of India has issued the Drugs (Second Amendment) Rules, 2026, introducing an important regulatory update by including Pregabalin under Schedule H1…

Continue ReadingIndia Updates Schedule H1: Pregabalin Added Under Drugs Rules, 1945

FDA Releases Revised Guidance on Assessing Food Effects in INDs and NDAs

Date of Publication: 20-May-2026 INTELLIGENCE OVEERVIEWAgency: USFDAThe U.S. Food and Drug Administration (FDA) has issued a revised guidance titled “Assessing the Effects of Food on Drugs in INDs and NDAs…

Continue ReadingFDA Releases Revised Guidance on Assessing Food Effects in INDs and NDAs

FDA Releases New Guidance on Submitting Continuous Glucose Monitoring Data in Clinical Trials

Date of Publication: 06-May-2026 INTELLIGENCE OVERVIEWAgency: USFDAThe U.S. Food and Drug Administration (FDA) has released a new technical guidance document titled , providing industry recommendations for the standardized submission of…

Continue ReadingFDA Releases New Guidance on Submitting Continuous Glucose Monitoring Data in Clinical Trials

FDA Releases Final Guidance on Patient-Matched Guides for Orthopedic Implants

Date of Publication: 07-May-2026 INTELLIGENCE OVERVIEWAgency: USFDAThe U.S. Food and Drug Administration (FDA) has issued its final guidance titled “Patient-Matched Guides for Orthopedic Implants.” The document provides recommendations for manufacturers…

Continue ReadingFDA Releases Final Guidance on Patient-Matched Guides for Orthopedic Implants

EMA Updates Guidance on Orphan Medicinal Product Designation (Rev. 19)

Date of Publication: 14-Apr-2026 INTELLIGENCE OVERVIEWThe European Medicines Agency (EMA) has released an updated guidance (Revision 19, April 2026) on the procedural advice for orphan medicinal product designation, offering a…

Continue ReadingEMA Updates Guidance on Orphan Medicinal Product Designation (Rev. 19)

Draft Amendment to Medical Devices Rules, 2017 Released for Public Consultation

Date of Publication: 10-Apr-2026 INTELLIGENCE OVERVIEWAgency: Official Gazette of India/MHFWThe Ministry of Health and Family Welfare has published a draft amendment to the Medical Devices Rules, 2017 on 10 April…

Continue ReadingDraft Amendment to Medical Devices Rules, 2017 Released for Public Consultation

EMA Revises Guideline for Clinical Investigation of SCIg/IMIg Products

INTELLIGENCE OVERVIEWAgency: EMAThe European Medicines Agency (EMA) has released Revision 2 of its guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg), adopted by…

Continue ReadingEMA Revises Guideline for Clinical Investigation of SCIg/IMIg Products